Vanguard Capital Management
PLRX icon

Vanguard Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Vanguard Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.6M Sell
2,408,462
-31,889
-1% -$35.4K ﹤0.01% 3295
2026
Q2 		$2.78M Buy
2,440,351
+97,250
+4% +$118K ﹤0.01% 3310
2026
Q1 		$2.95M Buy
+2,343,101
New +$2.96M ﹤0.01% 3242

Other funds holding PLRX

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Monaco Asset Management
Monaco Asset Management Monaco $818M AUM 32.61% 1-Year Est. Return
Prosight Management
Prosight Management Dallas, Texas $515M AUM 2.95% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
Peapod Lane Capital
Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Vanguard Capital Management's PLRX Position: Q3 2026 in Review

Vanguard Capital Management reduced its Pliant Therapeutics (PLRX) stake by 1.3% in Q3 2026, selling an estimated $35.4K and leaving 2,408,462 shares worth $2.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3295.

Vanguard Capital Management first reported a position in PLRX in Q1 2026 and has held it in 3 quarters since. The position peaked at $2.95M in Q1 2026. 49 funds tracked by Wall St. Rank hold PLRX as of Q3 2026.

  • Vanguard Capital Management held 2,408,462 shares of Pliant Therapeutics worth $2.6M as of Q3 2026.
  • Vanguard Capital Management sold 31,889 Pliant Therapeutics shares in Q3 2026, an estimated $35.4K.
  • Pliant Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3295 holding.
  • Vanguard Capital Management first reported a position in Pliant Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Pliant Therapeutics position peaked at $2.95M in Q1 2026.
  • 49 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.